Delta Asset Management LLC TN Purchases 38,141 Shares of Becton, Dickinson and Company $BDX

Delta Asset Management LLC TN lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 120,183 shares of the medical instruments supplier’s stock after purchasing an additional 38,141 shares during the period. Becton, Dickinson and Company accounts for 1.8% of Delta Asset Management LLC TN’s portfolio, making the stock its 16th largest holding. Delta Asset Management LLC TN’s holdings in Becton, Dickinson and Company were worth $20,702,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of BDX. Bill Few Associates Inc. increased its position in Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 55 shares during the last quarter. Gilbert & Cook Inc. lifted its position in shares of Becton, Dickinson and Company by 2.0% in the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 56 shares during the last quarter. Mendel Money Management boosted its stake in shares of Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after acquiring an additional 58 shares during the period. Plancorp LLC increased its holdings in shares of Becton, Dickinson and Company by 4.1% during the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock worth $343,000 after acquiring an additional 59 shares during the last quarter. Finally, Moody National Bank Trust Division raised its stake in Becton, Dickinson and Company by 2.4% in the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after acquiring an additional 60 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $192.93 on Monday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $186.66 and a two-hundred day simple moving average of $181.59. The stock has a market capitalization of $55.30 billion, a price-to-earnings ratio of 34.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,249 shares of company stock valued at $231,358 over the last ninety days. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada cut their price objective on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.